|
EP0939121B2
(de)
|
1989-09-12 |
2007-12-26 |
AHP Manufacturing B.V. |
TFN-bindende Proteine
|
|
US5635599A
(en)
|
1994-04-08 |
1997-06-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Fusion proteins comprising circularly permuted ligands
|
|
EP1027373B1
(en)
|
1997-10-31 |
2006-09-06 |
Biomira, Inc. |
Muc-1 derivatives and their use in treating cancer-associated muc-1 mucin-induced immunosuppression
|
|
WO1999046392A1
(en)
|
1998-03-12 |
1999-09-16 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
|
|
EP1066322A1
(en)
|
1998-04-03 |
2001-01-10 |
The University of Washington |
Circularly permuted biotin binding proteins
|
|
WO2000029447A1
(en)
|
1998-11-19 |
2000-05-25 |
Smithkline Beecham Corporation |
Rhamm antagonist antibodies
|
|
US6428985B1
(en)
|
1998-12-02 |
2002-08-06 |
The Regents Of The University Of Michigan |
Immunosuppressive structural definition of IL-10
|
|
US7754855B1
(en)
|
1999-07-13 |
2010-07-13 |
Bolder Biotechnology, Inc. |
Immunoglobulin fusion proteins
|
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
WO2001058950A1
(en)
|
2000-02-11 |
2001-08-16 |
Maxygen Aps |
Improved interleukin 10
|
|
EP1272467A4
(en)
|
2000-04-06 |
2003-05-07 |
Merck Frosst Canada Inc |
Cathepsin cysteine protease inhibitors
|
|
IL155812A0
(en)
|
2000-12-07 |
2003-12-23 |
Lilly Co Eli |
Glp-1 fusion proteins
|
|
JP2004519230A
(ja)
|
2001-02-06 |
2004-07-02 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
低減された免疫原性を有する修飾されたインターロイキン−１受容体アンタゴニスト（ｉｌ−１ｒａ）
|
|
CA2454469A1
(en)
|
2001-07-20 |
2003-02-06 |
Absorber, Ab |
Blood group antigen fusion polypeptides and methods of use thereof
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
EP1534748A2
(en)
|
2002-08-09 |
2005-06-01 |
Recopharma AB |
Fusion proteins and methods of producing same
|
|
AU2003280315A1
(en)
|
2002-11-14 |
2004-06-03 |
Maxygen, Inc. |
Conjugates of interleukin-10 and polymers
|
|
WO2004060911A2
(en)
|
2002-12-30 |
2004-07-22 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
|
PL2298347T3
(pl)
|
2003-05-06 |
2016-03-31 |
Bioverativ Therapeutics Inc |
Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
|
|
US7696322B2
(en)
|
2003-07-28 |
2010-04-13 |
Catalent Pharma Solutions, Inc. |
Fusion antibodies
|
|
US20150071948A1
(en)
|
2003-09-26 |
2015-03-12 |
Gregory Alan Lazar |
Novel immunoglobulin variants
|
|
WO2005034863A2
(en)
|
2003-10-03 |
2005-04-21 |
Jarikuma Corporation |
Countermeasures against malaria
|
|
WO2005042573A1
(en)
|
2003-10-24 |
2005-05-12 |
Dana-Farber Cancer Institute, Inc. |
Modulation of the interaction of muc1 with muc1 ligands
|
|
US8454963B2
(en)
|
2003-11-13 |
2013-06-04 |
Musc Foundation For Research Development |
Tissue targeted complement modulators
|
|
US7576183B2
(en)
|
2003-12-24 |
2009-08-18 |
Los Alamos National Security, Llc |
Structure-based receptor MIMICS targeted against bacterial superantigen toxins
|
|
CA2583983C
(en)
|
2004-10-14 |
2013-07-16 |
Abbott Gmbh & Co. Kg |
Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
|
|
MX2007006214A
(es)
|
2004-11-24 |
2008-04-16 |
Therakine Ltd |
Un implante para suministro de farmaco intraocular.
|
|
CN101163477A
(zh)
|
2005-02-23 |
2008-04-16 |
普雷萨药品公司 |
多介质多巴胺转运抑制剂，以及其相关应用
|
|
CA2618791C
(en)
|
2005-08-12 |
2014-05-13 |
Riken |
Novel mucin-type glycoprotein and use thereof
|
|
US20100016547A1
(en)
|
2005-11-30 |
2010-01-21 |
Takaomi Ito |
Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient
|
|
DE602005015733D1
(de)
|
2005-12-02 |
2009-09-10 |
Apceth Gmbh & Co Kg |
Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration
|
|
WO2008140595A2
(en)
|
2006-12-01 |
2008-11-20 |
President And Fellows Of Harvard College |
Synthetic trivalent haptens, complexes thereof, and uses therefor
|
|
CA2682849C
(en)
|
2007-04-03 |
2012-05-29 |
Pfizer Inc. |
Sulfonamides and pharmaceutical compositions thereof
|
|
WO2008133928A2
(en)
|
2007-04-27 |
2008-11-06 |
The Gi Company, Inc. |
Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
|
|
JP2010536341A
(ja)
|
2007-08-15 |
2010-12-02 |
アムニクス， インコーポレイテッド |
生物学的に活性なポリペプチドの特性を改変するための組成物および方法
|
|
AU2008335360A1
(en)
|
2007-12-06 |
2009-06-18 |
Pain Therapeutics, Inc. |
Micronized opioid compositions, formulations and dosage forms and methods of making same
|
|
US8258163B2
(en)
|
2008-06-04 |
2012-09-04 |
Board Of Regents, The University Of Texas System |
Small-molecule agonists for type-2 orexin receptor
|
|
US8765669B2
(en)
|
2008-06-17 |
2014-07-01 |
Glytech, Inc. |
Glycosylated GLP-1 peptide
|
|
ES2411916T3
(es)
|
2008-08-14 |
2013-07-09 |
Janssen R&D Ireland |
Derivados indólicos macrocíclicos útiles como inhibidores del virus de la hepatitis c
|
|
EP3028707A1
(en)
|
2009-05-01 |
2016-06-08 |
Ophthotech Corporation |
Methods for treating or preventing ophthalmological diseases
|
|
BRPI1014583B1
(pt)
|
2009-06-26 |
2020-03-31 |
Pfizer, Inc. |
Sulfonamidas heterocíclicas e composições farmacêuticas
|
|
BR112012017164A2
(pt)
|
2009-12-22 |
2019-09-24 |
Novartis Ag |
proteína de fusão de região constante de anticorpo-cd47 tetravalente
|
|
CA2785907A1
(en)
|
2009-12-29 |
2011-07-28 |
Emergent Product Development Seattle, Llc |
Ron binding constructs and methods of use thereof
|
|
AR080993A1
(es)
|
2010-04-02 |
2012-05-30 |
Hanmi Holdings Co Ltd |
Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
|
|
CN101962413B
(zh)
|
2010-09-21 |
2013-03-13 |
中国科学技术大学 |
具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用
|
|
US8883134B2
(en)
|
2010-10-20 |
2014-11-11 |
Handok Pharmaceuticals, Inc. |
Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
|
|
EP2457579A1
(en)
|
2010-11-26 |
2012-05-30 |
Technische Universität Dresden |
Covalently linked interleukin -10
|
|
TWI743461B
(zh)
|
2011-03-28 |
2021-10-21 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
|
EP2694472B1
(en)
*
|
2011-04-05 |
2020-03-11 |
Takeda Pharmaceutical Company Limited |
Sulfonamide derivative and use thereof
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
EP2723380B1
(en)
|
2011-06-24 |
2019-08-21 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
NO2748201T3
(https=)
|
2011-08-23 |
2018-05-12 |
|
|
|
US10017481B2
(en)
|
2012-03-17 |
2018-07-10 |
Polyphor Ag |
Conformationally constrained, fully synthetic macrocyclic compounds
|
|
US9062120B2
(en)
|
2012-05-02 |
2015-06-23 |
Janssen Biotech, Inc. |
Binding proteins having tethered light chains
|
|
EP2851429B1
(en)
|
2012-05-18 |
2019-07-24 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
|
US9156897B2
(en)
|
2012-06-08 |
2015-10-13 |
Alkermes, Inc. |
Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
|
|
IN2015DN01299A
(https=)
|
2012-07-23 |
2015-07-03 |
Zymeworks Inc |
|
|
PE20150645A1
(es)
|
2012-08-08 |
2015-05-11 |
Roche Glycart Ag |
Proteinas de fusion de interleuquina 10 y usos de las mismas
|
|
US11634502B2
(en)
|
2013-03-15 |
2023-04-25 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
EP2989240A4
(en)
|
2013-04-24 |
2016-10-19 |
Armo Biosciences Inc |
INTERLEUKIN-10 COMPOSITIONS AND USES THEREOF
|
|
WO2014198880A1
(en)
|
2013-06-14 |
2014-12-18 |
Ferrer Internacional, S.A. |
2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
|
|
CA2919076C
(en)
|
2013-07-31 |
2024-01-30 |
Amgen Inc. |
Stabilization of fc-containing polypeptides
|
|
US20160250224A1
(en)
|
2013-09-24 |
2016-09-01 |
The Board Of Regents Of The University Of Texas System |
Orexin-control of bone formation and loss
|
|
CA2930693A1
(en)
|
2013-11-15 |
2015-05-21 |
The Board Of Trustees Of The Leland Stanford Junior Unversity |
Methods of treating heart failure with agonists of hypocretin receptor 2
|
|
PE20161064A1
(es)
|
2013-12-12 |
2016-10-28 |
Univ Tsukuba |
Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo
|
|
WO2015117930A1
(en)
|
2014-02-06 |
2015-08-13 |
F. Hoffmann-La Roche Ag |
Interleukine 10 immunoconjugates
|
|
WO2015147240A1
(ja)
|
2014-03-28 |
2015-10-01 |
国立大学法人筑波大学 |
敗血症の予防治療剤
|
|
KR102455043B1
(ko)
|
2014-09-11 |
2022-10-13 |
얀센 파마슈티카 엔.브이. |
치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도
|
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
AU2015364396B2
(en)
|
2014-12-19 |
2018-08-09 |
Alkermes, Inc. |
Single chain Fc fusion proteins
|
|
WO2016101119A1
(en)
|
2014-12-23 |
2016-06-30 |
Merck Sharp & Dohme Corp. |
Fused heteroaryl derivatives as orexin receptor antagonists
|
|
WO2016133160A1
(ja)
|
2015-02-19 |
2016-08-25 |
国立大学法人筑波大学 |
スルホンアミド誘導体またはその薬学的に許容される酸付加塩
|
|
WO2016199906A1
(ja)
|
2015-06-12 |
2016-12-15 |
国立大学法人筑波大学 |
スルホンアミド誘導体またはその薬学的に許容される酸付加塩
|
|
CN107787322B
(zh)
|
2015-06-17 |
2023-07-07 |
辉瑞大药厂 |
三环化合物以及它们作为磷酸二酯酶抑制剂的用途
|
|
BR112018003588A2
(pt)
|
2015-08-26 |
2018-09-25 |
Blueprint Medicines Corp |
compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk
|
|
US20170114098A1
(en)
|
2015-09-03 |
2017-04-27 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
CN108699065B
(zh)
|
2015-12-18 |
2021-08-31 |
诺华股份有限公司 |
作为激酶抑制剂的三环类化合物和组合物
|
|
PL3411358T3
(pl)
|
2016-02-04 |
2022-02-28 |
Takeda Pharmaceutical Company Limited |
Podstawiony związek piperydynowy i jego zastosowanie
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
WO2018005226A2
(en)
|
2016-06-22 |
2018-01-04 |
Alkermes, Inc. |
Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
|
|
US11034700B2
(en)
|
2017-03-08 |
2021-06-15 |
Takeda Pharmaceutical Company Limited |
Substituted pyrrolidine compound and use thereof
|
|
WO2018164191A1
(ja)
|
2017-03-08 |
2018-09-13 |
武田薬品工業株式会社 |
置換ピロリジン化合物およびその用途
|
|
US20200207734A1
(en)
|
2017-08-03 |
2020-07-02 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
|
US11319286B2
(en)
|
2017-08-03 |
2022-05-03 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and application thereof
|
|
CN111132975B
(zh)
|
2017-09-28 |
2023-05-23 |
勃林格殷格翰国际有限公司 |
N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺
|
|
WO2019117148A1
(ja)
|
2017-12-12 |
2019-06-20 |
国立大学法人 筑波大学 |
スルホンアミド誘導体またはその薬学的に許容される酸付加塩
|
|
MX2020010155A
(es)
|
2018-03-27 |
2021-03-25 |
Univ Texas |
Compuestos de ox2r.
|
|
JP7413261B2
(ja)
|
2018-06-29 |
2024-01-15 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
|
US12077522B2
(en)
|
2018-06-29 |
2024-09-03 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and application thereof
|
|
JP7379374B2
(ja)
|
2018-12-12 |
2023-11-14 |
武田薬品工業株式会社 |
複素環化合物
|
|
EP3896060B1
(en)
|
2018-12-12 |
2023-08-16 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
SG11202106791XA
(en)
|
2019-01-31 |
2021-07-29 |
Takeda Pharmaceuticals Co |
Heterocyclic compound and use thereof
|
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
|
WO2020167701A1
(en)
|
2019-02-13 |
2020-08-20 |
Merck Sharp & Dohme Corp. |
Pyrrolidine orexin receptor agonists
|
|
WO2021026047A1
(en)
|
2019-08-08 |
2021-02-11 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
|
BR112022004576A2
(pt)
|
2019-09-13 |
2022-06-14 |
Takeda Pharmaceuticals Co |
Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica
|
|
CN110642684B
(zh)
|
2019-10-15 |
2022-07-26 |
天津师范大学 |
一类基于联苯芳烃的大环和笼状分子及衍生化合物及其合成方法与应用
|
|
FI4065585T3
(fi)
|
2019-11-25 |
2025-09-26 |
Alkermes Inc |
Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
|
|
WO2021106975A1
(ja)
|
2019-11-27 |
2021-06-03 |
武田薬品工業株式会社 |
複素環化合物
|
|
US11352357B2
(en)
|
2019-11-27 |
2022-06-07 |
Sumitomo Dainippon Pharma Co., Ltd. |
Cycloalkylurea derivative
|
|
MX2022008392A
(es)
|
2020-01-10 |
2022-08-08 |
Takeda Pharmaceuticals Co |
Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.
|
|
KR20230040953A
(ko)
|
2020-07-17 |
2023-03-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
치환된 피페리딘 화합물 및 이의 적용례
|
|
BR112023002957A2
(pt)
|
2020-08-18 |
2023-04-04 |
Merck Sharp & Dohme Llc |
Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero
|
|
EP4199925A4
(en)
|
2020-08-18 |
2024-08-28 |
Merck Sharp & Dohme LLC |
CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS
|
|
US12503475B2
(en)
|
2020-09-03 |
2025-12-23 |
Centessa Pharmaceuticals (Uk) Limited |
Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
|
|
WO2022051583A1
(en)
|
2020-09-03 |
2022-03-10 |
Orexia Therapeutics Limited |
Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
|
|
JP2022064180A
(ja)
|
2020-10-13 |
2022-04-25 |
武田薬品工業株式会社 |
複素環化合物
|
|
EP4236938A4
(en)
|
2020-11-02 |
2024-10-16 |
Merck Sharp & Dohme LLC |
MACROCYCLIC UREA-OREX RECEPTOR AGONISTS
|
|
WO2022109117A1
(en)
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists
|
|
EP4255429A4
(en)
|
2020-12-03 |
2024-12-11 |
Merck Sharp & Dohme LLC |
3-heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
|
US20240101555A1
(en)
|
2020-12-16 |
2024-03-28 |
Merck Sharp & Dohme Llc |
Urea orexin receptor agonists
|
|
US12006330B2
(en)
|
2020-12-21 |
2024-06-11 |
Alkermes, Inc. |
Substituted macrocyclic compounds and related methods of treatment
|
|
US11760747B2
(en)
|
2020-12-21 |
2023-09-19 |
Alkermes, Inc. |
Substituted piperidino compounds and related methods of treatment
|
|
US20240174605A1
(en)
|
2021-03-03 |
2024-05-30 |
Research Triangle Institute |
Arylsulfonamides as orexin receptor agonists
|
|
WO2022207935A1
(en)
|
2021-04-02 |
2022-10-06 |
Orexia Therapeutics Limited |
2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
|
|
KR20240004802A
(ko)
|
2021-05-03 |
2024-01-11 |
재즈 파마슈티칼즈 아일랜드 리미티드 |
오렉신 수용체 효능제 및 그의 용도
|
|
CA3219888A1
(en)
|
2021-05-26 |
2022-12-01 |
Masafumi KOMIYA |
Phenyl urea derivative
|
|
EP4359387A1
(en)
|
2021-06-25 |
2024-05-01 |
Jazz Pharmaceuticals Ireland Limited |
Sulfonamide orexin receptor agonists and uses thereof
|
|
WO2023017180A1
(en)
|
2021-08-13 |
2023-02-16 |
Orexia Therapeutics Limited |
Peptide derivatives and related uses as orexin agonists
|